These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17961659)

  • 1. [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].
    Roussel R
    Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():33-5. PubMed ID: 17961659
    [No Abstract]   [Full Text] [Related]  

  • 2. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke].
    MMW Fortschr Med; 2006 Aug; 148(35-36):48. PubMed ID: 16995368
    [No Abstract]   [Full Text] [Related]  

  • 4. The endocannabinoid system: a promising target for the management of type 2 diabetes.
    Scheen AJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.
    Rosenstock J; Hollander P; Chevalier S; Iranmanesh A;
    Diabetes Care; 2008 Nov; 31(11):2169-76. PubMed ID: 18678611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
    Scheen AJ; Paquot N; Van Gaal LF
    Rev Med Suisse; 2008 Aug; 4(168):1812-7. PubMed ID: 18814765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
    Scheen AJ; Finer N; Hollander P; Jensen MD; Van Gaal LF;
    Lancet; 2006 Nov; 368(9548):1660-72. PubMed ID: 17098084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
    Christopoulou FD; Kiortsis DN
    J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
    Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
    J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.
    Jin SM; Oh BJ; Lee S; Choi JM; Yang SJ; Park SW; Kim KW; Kim JH; Park CY
    Yonsei Med J; 2013 Sep; 54(5):1127-36. PubMed ID: 23918561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.
    Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994
    [No Abstract]   [Full Text] [Related]  

  • 14. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
    Dibble CT; Gelfand EV; Cannon CP
    Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
    Golay A
    Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
    Scheen AJ; Paquot N
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
    Prescrire Int; 2006 Aug; 15(84):123-6. PubMed ID: 16977739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hope and fear of rimonabant.
    Rumsfeld JS; Nallamothu BK
    JAMA; 2008 Apr; 299(13):1601-2. PubMed ID: 18387935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.